| Study | Research area | Depression | Control | Actigraphy | Outcome |
|---|
| Sample size/n | Age/year | Sex (male/female)/n | Diagnostic criteria | Sample size/n | Age/year | Sex (male/female)/n | Instrument model | Wearing time/d | |
|---|
ROBILLARD, 2015[17] | Australia | 135 | 20.0±4.4 | 47/88 | DSM | 41 | 25.3±5.8 | 19/22 | Actiwatch-64/L/2, Philips Respironics | 4‒22 | ①③⑥⑦ | | MERIKANTO, 2017[18] | Finland | 8 | 16.0±1.1 | 8/0 | K-SADS-PL | 9 | 16.0±0.7 | 9/0 | Actiwatch-Plus®, Cambridge Neurotechnology Ltd, Cambridge, UK | 23 | ①④⑤ | | SLYEPCHENKO, 2019[19] | Canada | 38 | 39 (22.75) | 13/25 | MINI | 40 | 30 (20) | 20/20 | Actiwatch 2 monitor | 15 | ①②③④⑤ | | MINAEVA, 2020[20] | The Netherlands | 58 | 52.34±10.59 | 22/36 | CIDI | 63 | 51.94±12.05 | 34/29 | GENEActiv actigraphy | 14 | ①②③ | | PYE, 2021[21] | Australia | 27 | 62.7±8.1 | 8/19 | MINI | 47 | 63.1±8.1 | 19/28 | Respironics Actiwatch Spectrum | 14 | ①②③④⑤⑥⑦ | | TONON, 2022[22] | Brazil | 39 | 16.1±0.7 | 19/20 | K-SADS-PL | 26 | 15.4±0.8 | 16/10 | ActTrust Condor | 10 | ②③④⑤⑥⑦ | | ROBILLARD, 2013[23] | Australia | 46 | 20.1±4.7 | 17/29 | DSM-IV | 20 | 24.8±2.5 | 8/12 | Actiwatch64, Philips Respironics, OR | 7 | ⑥⑦ | | ROBILLARD, 2018[24] | Australia | 35 | 21.1±2.9 | 14/21 | DSM-IV | 15 | 24.3±3.4 | 7/8 | Actiwatch64/L/2, Philips Respironics, USA or GENEActiv, Activinsights, UK | 12 | ⑥⑦ | | MCGLASHAN, 2019[25] | Australia | 8 | 24.25±2.12 | 0/8 | DSM-IV-TR | 31 | 21.19±2.65 | 0/31 | Actiwatch Spectrum, PLUS, PRO, 2 or L, Philips Respironics, OR, USA | 7 | ⑥⑦ |
|